Dynamics of changes in self-efficacy and locus of control expectancies in the behavioral and drug treatment of severe migraine

Ann Behav Med. 2010 Dec;40(3):235-47. doi: 10.1007/s12160-010-9223-3.

Abstract

Background: Modification of expectancies (headache self-efficacy and headache locus of control) is thought to be central to the success of psychological treatments for migraine.

Purpose: The purpose of this study is to examine expectancy changes with various combinations of Behavioral Migraine Management and migraine drug therapies.

Methods: Frequent migraine sufferers who failed to respond to 5 weeks of optimized acute migraine drug therapy were randomized to a 2 (Behavioral Migraine Management+, Behavioral Migraine Management-) × 2 (β-blocker, placebo) treatment design.

Results: Mixed models for repeated measures analyses (N = 176) revealed large increases in headache self-efficacy and internal headache locus of control and large decreases in chance headache locus of control with Behavioral Migraine Management+ that were maintained over a 12-month evaluation period. Chance headache locus of control and socioeconomic status moderated changes in headache self-efficacy with Behavioral Migraine Management+.

Conclusions: The "deficiency" hypothesis best explained how patient characteristics influenced changes in of headache self-efficacy with Behavioral Migraine Management.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Analysis of Variance
  • Chi-Square Distribution
  • Cognitive Behavioral Therapy / methods*
  • Double-Blind Method
  • Female
  • Humans
  • Internal-External Control*
  • Middle Aged
  • Migraine Disorders / psychology*
  • Migraine Disorders / therapy*
  • Patient Satisfaction
  • Propranolol / therapeutic use*
  • Quality of Life
  • Self Efficacy*
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Propranolol